Andrea Ropero-Herencia

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

Journal: Science translational medicine
Published: March 18, 2026

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Journal: NPJ precision oncology
Published: January 23, 2026

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.

Journal: Cell reports
Published: June 18, 2025

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.

Journal: NPJ precision oncology
Published: June 17, 2025

DNA topoisomerase IIß inhibition blocks DNA end resection and synergizes with PARPi in BRCA1-deficient models.

DNA topoisomerase IIß inhibition blocks DNA end resection and synergizes with PARPi in BRCA1-deficient models.

Journal: DNA repair
Published: February 12, 2025

Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.

Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.

Journal: NAR cancer
Published: October 17, 2024

RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial.

RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 25, 2024

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer.

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer.

Journal: Cancer research
Published: July 23, 2024

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.

Journal: Genome medicine
Published: February 13, 2024

Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers.

Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers.

Journal: NPJ precision oncology
Published: January 24, 2024

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.

Journal: JCO precision oncology
Published: December 01, 2023

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer.

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer.

Journal: EMBO molecular medicine
Published: August 03, 2023
Showing 1-12 of 21

Last Updated: 09/26/2026